ATC code L01

ATC codes

L Antineoplastic and immunomodulating agents

L02 Endocrine therapy

ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup L01 is part of the anatomical group L Antineoplastic and immunomodulating agents.^[1]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL01.^[2] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

L01A Alkylating agents

L01B Antimetabolites

L01BA Folic acid analogues

L01BA01 Methotrexate

L01BA03 Raltitrexed

L01BA04 Pemetrexed

L01BA05 Pralatrexate

L01BB Purine analogues

L01BB02 Mercaptopurine

L01BB03 Tioguanine

L01BB04 Cladribine

L01BB05 Fludarabine

L01BB06 Clofarabine

L01BB07 Nelarabine

L01BC Pyrimidine analogues

L01BC01 Cytarabine

L01BC02 Fluorouracil

L01BC03 Tegafur

L01BC04 Carmofur

L01BC05 Gemcitabine

L01BC06 Capecitabine

L01BC07 Azacitidine

L01BC08 Decitabine

L01BC52 Fluorouracil, combinations

L01BC53 Tegafur, combinations

L01BC59 Trifluridine, combinations

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

L01CA01 Vinblastine

L01CA02 Vincristine

L01CA03 Vindesine

L01CA04 Vinorelbine

L01CA05 Vinflunine

L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

L01CB01 Etoposide

L01CB02 Teniposide

L01CC Colchicine derivatives

L01CC01 Demecolcine

L01CD Taxanes

L01CD01 Paclitaxel

L01CD02 Docetaxel

L01CD03 Paclitaxel poliglumex

L01CD04 Cabazitaxel

L01CX Other plant alkaloids and natural products

L01CX01 Trabectedin

L01D Cytotoxic antibiotics and related substances

L01DA Actinomycines

L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

L01DB01 Doxorubicin

L01DB02 Daunorubicin

L01DB03 Epirubicin

L01DB04 Aclarubicin

L01DB05 Zorubicin

L01DB06 Idarubicin

L01DB07 Mitoxantrone

L01DB08 Pirarubicin

L01DB09 Valrubicin

L01DB10 Amrubicin

L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

L01DC01 Bleomycin

L01DC02 Plicamycin

L01DC03 Mitomycin

L01DC04 Ixabepilone

L01X Other antineoplastic agents

L01XA Platinum compounds

L01XA01 Cisplatin

L01XA02 Carboplatin

L01XA03 Oxaliplatin

L01XA04 Satraplatin

L01XA05 Polyplatillen

L01XB Methylhydrazines

L01XB01 Procarbazine

L01XC Monoclonal antibodies

L01XC01 Edrecolomab

L01XC02 Rituximab

L01XC03 Trastuzumab

L01XC05 Gemtuzumab

L01XC06 Cetuximab

L01XC07 Bevacizumab

L01XC08 Panitumumab

L01XC09 Catumaxomab

L01XC10 Ofatumumab

L01XC11 Ipilimumab

L01XC12 Brentuximab vedotin

L01XC13 Pertuzumab

L01XC14 Trastuzumab emtansine

L01XC15 Obinutuzumab

L01XC16 Dinutuximab

L01XC17 Nivolumab

L01XC18 Pembrolizumab

L01XC19 Blinatumomab

L01XC21 Ramucirumab

L01XC22 Necitumumab

L01XD Sensitizers used in photodynamic/radiation therapy

L01XD01 Porfimer sodium

L01XD03 Methyl aminolevulinate

L01XD04 Aminolevulinic acid

L01XD05 Temoporfin

L01XD06 Efaproxiral

L01XE Protein kinase inhibitors

L01XE01 Imatinib

L01XE02 Gefitinib

L01XE03 Erlotinib

L01XE04 Sunitinib

L01XE05 Sorafenib

L01XE06 Dasatinib

L01XE07 Lapatinib

L01XE08 Nilotinib

L01XE09 Temsirolimus

L01XE10 Everolimus

L01XE11 Pazopanib

L01XE12 Vandetanib

L01XE13 Afatinib

L01XE14 Bosutinib

L01XE15 Vemurafenib

L01XE16 Crizotinib

L01XE17 Axitinib

L01XE18 Ruxolitinib

L01XE19 Ridaforolimus

L01XE21 Regorafenib

L01XE22 Masitinib

L01XE23 Dabrafenib

L01XE24 Ponatinib

L01XE25 Trametinib

L01XE26 Cabozantinib

L01XE27 Ibrutinib

L01XE28 Ceritinib

L01XE29 Lenvatinib

L01XE31 Nintedanib

L01XE32 Cediranib

L01XE33 Palbociclib

L01XE34 Tivozanib

QL01XE91 Toceranib

L01XX Other antineoplastic agents

L01XX01 Amsacrine

L01XX02 Asparaginase

L01XX03 Altretamine

L01XX05 Hydroxycarbamide

L01XX07 Lonidamine

L01XX08 Pentostatin

L01XX09 Miltefosine

L01XX10 Masoprocol

L01XX11 Estramustine

L01XX14 Tretinoin

L01XX16 Mitoguazone

L01XX17 Topotecan

L01XX18 Tiazofurine

L01XX19 Irinotecan

L01XX22 Alitretinoin

L01XX23 Mitotane

L01XX24 Pegaspargase

L01XX25 Bexarotene

L01XX27 Arsenic trioxide

L01XX29 Denileukin diftitox

L01XX32 Bortezomib

L01XX33 Celecoxib

L01XX35 Anagrelide

L01XX36 Oblimersen

L01XX37 Sitimagene ceradenovec

L01XX38 Vorinostat

L01XX39 Romidepsin

L01XX40 Omacetaxine mepesuccinate

L01XX41 Eribulin

L01XX42 Panobinostat

L01XX43 Vismodegib

L01XX44 Aflibercept

L01XX45 Carfilzomib

L01XX46 Olaparib

L01XX47 Idelalisib

L01XX48 Sonidegib

L01XX49 Belinostat

L01XX50 Ixazomib

References

↑ "ATC/DDD Index 2016: code L01". WHO Collaborating Centre for Drug Statistics Methodology.
↑ "ATCvet Index 2016: code QL01". WHO Collaborating Centre for Drug Statistics Methodology.

Intracellular chemotherapeutic agents / antineoplastic agents (L01)

SPs/MIs
(M phase)

Block microtubule assembly	Vinca alkaloids (Vinblastine^# Vincristine^# Vinflunine^§ Vindesine Vinorelbine)

Block microtubule disassembly	Taxanes (Cabazitaxel Docetaxel^# Larotaxel Ortataxel^† Paclitaxel^# Tesetaxel) Epothilones (Ixabepilone)

DNA replication
inhibitor

DNA precursors/
antimetabolites
(S phase)

Folic acid	Dihydrofolate reductase inhibitor (Aminopterin Methotrexate^# Pemetrexed Pralatrexate) Thymidylate synthase inhibitor (Raltitrexed Pemetrexed)

Purine	Adenosine deaminase inhibitor (Pentostatin) Halogenated/ribonucleotide reductase inhibitors (Cladribine Clofarabine Fludarabine) Nelarabine Thiopurine (Thioguanine^# Mercaptopurine^#)

Pyrimidine	Thymidylate synthase inhibitor (Fluorouracil^# Capecitabine Tegafur (+gimeracil/oteracil) Carmofur Floxuridine) DNA polymerase inhibitor (Cytarabine^#) Ribonucleotide reductase inhibitor (Gemcitabine) Hypomethylating agent (Azacitidine Decitabine)

Deoxyribonucleotide	Ribonucleotide reductase inhibitor (Hydroxycarbamide)

Topoisomerase inhibitors
(S phase)

I	Camptotheca (Camptothecin Cositecan^† Belotecan Gimatecan Exatecan Irinotecan Lurtotecan^‡ Silatecan^§ Topotecan Rubitecan^‡)

II	Podophyllum (Etoposide^# Teniposide)

II+Intercalation	Anthracyclines (Aclarubicin Daunorubicin^# Doxorubicin^# Epirubicin Idarubicin Amrubicin^† Pirarubicin Valrubicin Zorubicin) Anthracenediones (Mitoxantrone Pixantrone)

Crosslinking of DNA
(CCNS)

Alkylating	Nitrogen mustards: Mechlorethamine Cyclophosphamide^# (Ifosfamide Trofosfamide) Chlorambucil^# (Melphalan Prednimustine) Bendamustine Uramustine Estramustine Nitrosoureas: Carmustine Lomustine (Semustine) Fotemustine Nimustine Ranimustine Streptozocin Alkyl sulfonates: Busulfan (Mannosulfan Treosulfan) Aziridines: Carboquone ThioTEPA Triaziquone Triethylenemelamine

Platinum-based	Carboplatin Cisplatin Dicycloplatin Nedaplatin Oxaliplatin Satraplatin

Nonclassical	Hydrazines (Procarbazine^#) Triazenes (Dacarbazine^# Temozolomide) Altretamine Mitobronitol Pipobroman

Intercalation	Streptomyces (Actinomycin^# Bleomycin^# Mitomycin Plicamycin)

Photosensitizers/PDT

Other

Enzyme inhibitors	FI (Tipifarnib^§) CDK inhibitors (Alvocidib^† Seliciclib^† Palbociclib) PrI Bortezomib Carfilzomib Ixazomib PhI (Anagrelide) IMPDI (Tiazofurin^§) LI (Masoprocol) PARP inhibitor (Olaparib) HDAC (Belinostat Panobinostat Romidepsin Vorinostat) PIKI (Idelalisib)

Receptor antagonists	ERA (Atrasentan) Retinoid X receptor (Bexarotene) Sex steroid (Testolactone)

Other/ungrouped	Amsacrine Trabectedin Retinoids (Alitretinoin Tretinoin) Arsenic trioxide Asparagine depleters (Asparaginase^#/Pegaspargase) Celecoxib Demecolcine Elesclomol^§ Elsamitrucin Etoglucid Lonidamine Lucanthone Mitoguazone Mitotane Oblimersen^† Omacetaxine mepesuccinate Eribulin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Targeted therapy / extracellular chemotherapeutic agents/antineoplastic agents (L01)

CI monoclonal antibodies ("-mab")

Receptor tyrosine kinase	ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Trastuzumab Trastuzumab emtansine)

Others for solid tumors	EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab)

Leukemia/lymphoma	lymphoid: CD20 (Ibritumomab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab)

Tyrosine-kinase inhibitors ("-nib")

Receptor tyrosine kinase	ErbB: HER1/EGFR (Erlotinib Gefitinib Osimertinib Vandetanib) HER1/EGFR and HER2/neu Afatinib Lapatinib Neratinib RTK class III: C-kit and PDGFR (Axitinib Masitinib Pazopanib Sunitinib Sorafenib Toceranib) FLT3 (Lestaurtinib) VEGFR Axitinib Cediranib Lenvatinib Nintedanib Pazopanib Regorafenib Semaxanib Sorafenib Sunitinib Tivozanib Toceranib Vandetanib RET inhibitors: Vandetanib (also VEGFR and EGFR). Entrectinib (ALK, ROS1, NTRK). c-MET inhibitor: Cabozantinib (also VEGFR2).

Non-receptor	bcr-abl Imatinib Dasatinib Nilotinib Ponatinib Radotinib Src (Bosutinib) Janus kinase Lestaurtinib Momelotinib Ruxolitinib Pacritinib MAP2K Cobimetinib Selumetinib Trametinib Binimetinib EML4-ALK Alectinib Ceritinib Crizotinib Bruton's (Ibrutinib)